Gensight Biologics SA
PAR:SIGHT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.2815
0.522
|
Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one SIGHT stock under the Base Case scenario is 0.1711 EUR. Compared to the current market price of 0.3185 EUR, Gensight Biologics SA is Overvalued by 46%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Gensight Biologics SA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for SIGHT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Gensight Biologics SA
Balance Sheet Decomposition
Gensight Biologics SA
Current Assets | 13m |
Cash & Short-Term Investments | 6.9m |
Receivables | 1.3m |
Other Current Assets | 4.7m |
Non-Current Assets | 2m |
Long-Term Investments | 519k |
PP&E | 1.4m |
Intangibles | 66k |
Current Liabilities | 16.9m |
Accounts Payable | 4.8m |
Accrued Liabilities | 1.6m |
Other Current Liabilities | 10.5m |
Non-Current Liabilities | 23m |
Long-Term Debt | 16m |
Other Non-Current Liabilities | 6.9m |
Earnings Waterfall
Gensight Biologics SA
Revenue
|
2.4m
EUR
|
Operating Expenses
|
-39.5m
EUR
|
Operating Income
|
-37.1m
EUR
|
Other Expenses
|
5m
EUR
|
Net Income
|
-32.1m
EUR
|
Free Cash Flow Analysis
Gensight Biologics SA
EUR | |
Free Cash Flow | EUR |
SIGHT Profitability Score
Profitability Due Diligence
Gensight Biologics SA's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Gensight Biologics SA's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
SIGHT Solvency Score
Solvency Due Diligence
Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Score
Gensight Biologics SA's solvency score is 28/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SIGHT Price Targets Summary
Gensight Biologics SA
According to Wall Street analysts, the average 1-year price target for SIGHT is 0.3876 EUR with a low forecast of 0.3636 EUR and a high forecast of 0.42 EUR.
Dividends
Current shareholder yield for SIGHT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
SIGHT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).
Contact
IPO
Employees
Officers
The intrinsic value of one SIGHT stock under the Base Case scenario is 0.1711 EUR.
Compared to the current market price of 0.3185 EUR, Gensight Biologics SA is Overvalued by 46%.